After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?

Eli Lilly’s Kelonia buyout is worth $3.25 billion upfront and up to $7 billion including milestones, underscoring how aggressively Big Pharmas are paying for in vivo CAR-T assets. The article highlights a broader M&A wave, with recent deals including Lilly’s $2.4 billion Orna acquisition, AbbVie’s $2.1 billion Capstan deal, and Bristol Myers’ $1.5 billion Orbital purchase, while suggesting dealmaking may slow as targets become scarce. Still, the tone is constructive for the sector because early clinical data and dual oncology/autoimmune potential are supporting premium valuations across in vivo CAR-T.

Analysis

The strategic implication is not that in vivo CAR-T is “hot,” but that the category is entering a scarcity phase where platform ownership matters more than single-asset data. That favors the incumbents with existing autologous CAR-T franchises: they are buying optionality against eventual cannibalization, which is usually the right move when a technology threatens your installed base before it fully scales. The second-order effect is that capital will likely migrate toward enabling infrastructure—vector delivery, manufacturing, and outpatient administration—rather than just target discovery, because those bottlenecks determine whether the modality can move from 3-patient headline data to a reimbursable commercial product.

The market is underestimating how concentrated the remaining acquisition set has become. Once the obvious private targets are spoken for, deal flow should shift offshore and to earlier-stage structures, which means more option-like partnerships and fewer clean takeouts. That benefits names with platform breadth and multiple shots on goal, while penalizing mono-asset biotechs that need a premium exit before larger datasets de-risk the platform.

Near term, the key catalyst is not more M&A announcements; it is whether the first 40-50 patient datasets show manageable cytokine/toxicity profiles and feasible outpatient delivery. If that happens, the field re-rates again; if not, the current valuation stack will compress quickly because today’s premiums are built on a narrative of efficacy plus operational simplicity. The biggest contrarian risk is that the market may be overpricing speed of adoption: even if biology works, payer approval, site readiness, and manufacturing reproducibility can delay broad uptake by 12-24 months.

For public equities, the most asymmetric trade is not the obvious M&A winner but the incumbent with the most to lose from disruption. That creates a hedged long-basket / short-franchise structure that benefits from optionality without assuming linear upside in the disruptive technology. In parallel, offshore developers with clinical-stage assets can become takeover-proxy names if U.S. targets become too expensive or encumbered by existing partnerships.

Key Decisions for Investors

• Long ABBV vs short GILD over 3-6 months: ABBV retains upside optionality on in vivo CAR-T while GILD is more exposed to disruption of its existing cell therapy franchise; use as a relative-value hedge against a binary readout.
• Initiate a small long LEGN position into the next in vivo data catalyst (30-90 days): best public proxy for the market’s willingness to pay for clinical-stage validation; keep size modest because expectations are now elevated.
• Buy JNJ or NVS as potential strategic catch-up longs on a 6-12 month horizon: both are still under-owned in this theme, and any partnership or acquisition would force a fast re-rating from “missing the platform” to “catch-up via M&A.”
• Use call spreads on LEGN or a basket of platform names for event-driven exposure: prefer defined-risk upside because headline-driven moves are likely to be sharp, but follow-through depends on 40+ patient data, not first-patient anecdotes.
• Avoid chasing private-market proxy enthusiasm in names with existing partner encumbrances; prefer offshore/cleaner targets only if liquidity improves and the ownership structure allows a straightforward takeout.